Moving from opacity to transparency in pharmaceutical policy.

@article{Dhalla2008MovingFO,
  title={Moving from opacity to transparency in pharmaceutical policy.},
  author={Irfan A. Dhalla and Andreas Laupacis},
  journal={CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne},
  year={2008},
  volume={178 4},
  pages={428-31}
}
© 2008 Canadian Medical Association or its licensors 428 Physicians and patients should demand, and participants in the system should provide, transparency in all of the areas of drug approval and reimbursement (Table 1). The current situation, in which the evidence used to make decisions often remains secret and the decisions are not adequately explained to the public, is untenable. We wrote this commentary in response to the House of Commons Standing Committee on Health’s 2007 parliamentary… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
12 Extracted Citations
19 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…